Total submissions: 20
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001049315 | SCV001213360 | pathogenic | PRPH2-related disorder | 2025-01-18 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 172 of the PRPH2 protein (p.Arg172Trp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with autosomal dominant macular dystrophy (PMID: 8485576, 8747448). It has also been observed to segregate with disease in related individuals. This variant is also known as RDS p.Arg172Trp. ClinVar contains an entry for this variant (Variation ID: 13170). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt PRPH2 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PRPH2 function (PMID: 24463884). For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV000084981 | SCV001246205 | pathogenic | not provided | 2018-12-01 | criteria provided, single submitter | clinical testing | |
NEI Ophthalmic Genomics Laboratory, |
RCV001250348 | SCV001424668 | pathogenic | Retinitis pigmentosa | 2020-01-07 | criteria provided, single submitter | clinical testing | The variant NM_000322.4:c.514C>T in the PRPH2 gene has been previously studied(Nichols (1993) Invest Ophthalmol Vis Sci 34 1149). We found this variant in 13 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755792,CM930639). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS4, PP1-S, PM1, PM2, PP3, PP5] and classified NM_000322.4:c.514C>T in the PRPH2 gene as a Pathogenic mutation. |
NEI Ophthalmic Genomics Laboratory, |
RCV001250349 | SCV001424669 | pathogenic | Patterned dystrophy of the retinal pigment epithelium | 2020-01-07 | criteria provided, single submitter | clinical testing | The variant NM_000322.4:c.514C>T in the PRPH2 gene has been previously studied(Nichols (1993) Invest Ophthalmol Vis Sci 34 1149). We found this variant in 13 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755792,CM930639). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS4, PP1-S, PM1, PM2, PP3, PP5] and classified NM_000322.4:c.514C>T in the PRPH2 gene as a Pathogenic mutation. |
NEI Ophthalmic Genomics Laboratory, |
RCV001250350 | SCV001424670 | pathogenic | Cone-rod dystrophy | 2020-01-07 | criteria provided, single submitter | clinical testing | The variant NM_000322.4:c.514C>T in the PRPH2 gene has been previously studied(Nichols (1993) Invest Ophthalmol Vis Sci 34 1149). We found this variant in 13 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755792,CM930639). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS4, PP1-S, PM1, PM2, PP3, PP5] and classified NM_000322.4:c.514C>T in the PRPH2 gene as a Pathogenic mutation. |
NEI Ophthalmic Genomics Laboratory, |
RCV001250351 | SCV001424672 | pathogenic | Vitelliform macular dystrophy 2 | 2020-01-07 | criteria provided, single submitter | clinical testing | The variant NM_000322.4:c.514C>T in the PRPH2 gene has been previously studied(Nichols (1993) Invest Ophthalmol Vis Sci 34 1149). We found this variant in 13 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755792,CM930639). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS4, PP1-S, PM1, PM2, PP3, PP5] and classified NM_000322.4:c.514C>T in the PRPH2 gene as a Pathogenic mutation. |
NEI Ophthalmic Genomics Laboratory, |
RCV001250352 | SCV001424673 | pathogenic | Stargardt disease | 2020-01-07 | criteria provided, single submitter | clinical testing | The variant NM_000322.4:c.514C>T in the PRPH2 gene has been previously studied(Nichols (1993) Invest Ophthalmol Vis Sci 34 1149). We found this variant in 13 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755792,CM930639). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS4, PP1-S, PM1, PM2, PP3, PP5] and classified NM_000322.4:c.514C>T in the PRPH2 gene as a Pathogenic mutation. |
Institute of Medical Genetics and Applied Genomics, |
RCV000084981 | SCV001447838 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Institute of Medical Molecular Genetics, |
RCV001352972 | SCV001548052 | likely pathogenic | Patterned macular dystrophy 1 | 2021-01-30 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV002466402 | SCV002761618 | pathogenic | Retinitis pigmentosa 7 | 2021-10-08 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000084981 | SCV003930252 | pathogenic | not provided | 2023-05-30 | criteria provided, single submitter | clinical testing | Reported as a common pathogenic variant among individuals of British background (Payne et al., 1998); Published functional studies in mice demonstrate a damaging effect with defective cone photoreceptors and abnormal PRPH2(RDS)/ROM-1 complex formation (Ding et al., 2004; Conley et al., 2014); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21405999, 8747448, 20335603, 32531858, 18055786, 34828423, 10800708, 24463884, 9010868, 8943002, 24608669, 8302543, 8015786, 29343940, 8485576, 7493155, 22183351, 29555955, 19279306, 28838317, 31456290, 32531846, 32036094, 9810570, 33691693, 26667666, 15254014, 9443872, 34411390, 10532447) |
Dept Of Ophthalmology, |
RCV003887869 | SCV004707350 | pathogenic | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Institute of Human Genetics, |
RCV003887869 | SCV005070996 | pathogenic | Retinal dystrophy | 2018-01-01 | criteria provided, single submitter | clinical testing | |
Sing |
RCV001352972 | SCV005881540 | likely pathogenic | Patterned macular dystrophy 1 | 2025-02-05 | criteria provided, single submitter | clinical testing | Variant is located in a mutational hotspot where >50% of variants are pathogenic (PM1). Experimental studies have shown that this missense change affects PRPH2 function (PMID:24463884;15254014). Cosegregation with disease has been found in multiple families in multiple studies (PMID:8747448;20335603;9443872) |
OMIM | RCV000014056 | SCV000034303 | pathogenic | Choroidal dystrophy, central areolar 2 | 1998-01-01 | no assertion criteria provided | literature only | |
Retina International | RCV000084981 | SCV000117117 | not provided | not provided | no assertion provided | not provided | ||
Sharon lab, |
RCV001003147 | SCV001161216 | likely pathogenic | maculopathy | 2019-06-23 | no assertion criteria provided | research | |
Leiden Open Variation Database | RCV000084981 | SCV001744958 | pathogenic | not provided | 2021-04-27 | no assertion criteria provided | curation | Curator: Global Variome, with Curator vacancy. Submitters to LOVD: Global Variome, with Curator vacancy, IMGAG, Julia Lopez, LOVD, Manon Peeters, Yoshito Koyanagi. |
Clinical Genetics, |
RCV000084981 | SCV001922523 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000084981 | SCV001952194 | pathogenic | not provided | no assertion criteria provided | clinical testing |